1.  Introduction

The global weight-management pharmaceutical industry is witnessing an important development with the introduction of oral weight-loss medicines. Until recently, patients interested in GLP-1 (glucagon-like peptide-1)-based treatments for obesity generally had to depend on weekly injections. However, a new development has created an alternative: a daily tablet containing semaglutide, marketed under the brand name Wegovy.

On 3 November 2026, Australia's Therapeutic Goods Administration (TGA) approved the oral version of Wegovy for use in the country. This makes it the first GLP-1 weight-loss medicine approved in Australia in tablet form.

Manufactured by Danish pharmaceutical company Novo Nordisk, the medicine is expected to provide an alternative for eligible patients who prefer tablets to injections.

However, approval does not necessarily mean it will be available in pharmacies immediately. Questions concerning its effectiveness, eligibility, safety, pricing, and commercial launch remain important for prospective patients.

Let's examine the development and its potential implications for Australia's healthcare and pharmaceutical markets.

2. Wegovy Pill – A Short Note

Wegovy is a prescription medicine developed by Novo Nordisk. Its active ingredient is semaglutide, which belongs to a group of medicines called GLP-1 receptor agonists.

GLP-1 stands for glucagon-like peptide-1, a naturally occurring hormone involved in regulating appetite and blood glucose levels.

Semaglutide works by:

Ø Reducing hunger and food cravings.

Ø Increasing feelings of fullness after meals.

Ø Slowing the movement of food through the stomach.

Ø Helping regulate blood glucose levels.

These effects can help patients consume fewer calories and achieve weight reduction.

Unlike the conventional Wegovy injection, which is administered once weekly, the tablet is designed for daily use.

An important distinction is that oral semaglutide requires a higher nominal dose than injectable semaglutide because only a small proportion of the medicine is absorbed through the digestive system.

3. Australia's TGA Approval

Australia's Therapeutic Goods Administration approved the Wegovy tablet on 3 November 2026.  The decision represents a significant development in Australia's obesity-treatment market because patients now have an approved oral GLP-1 option for weight management.

The approval covers eligible patients requiring chronic weight management and certain patients needing cardiovascular risk reduction.

However, there is an important qualification.  Although the medicine has received regulatory approval, the TGA still needs to complete its review of packaging and production processes before the product can be released commercially.

Why is this approval important?

i.  It introduces an oral alternative to injectable GLP-1 medicines.

ii.  It expands treatment choices for eligible patients.

iii.  It strengthens competition in the obesity-treatment pharmaceutical market.

iv.  It may encourage further innovation in oral weight-management medicines.

The development also creates new opportunities for pharmaceutical companies competing in the rapidly expanding obesity-treatment industry.

4. Wegovy's Demand in the US and UK

The introduction of oral Wegovy has attracted considerable attention in international pharmaceutical markets.

a.  United States

The US Food and Drug Administration (FDA) approved the Wegovy tablet, and commercial availability began on 5 January 2026.  The medicine recorded an impressive market response.

According to Novo Nordisk, the company announced that Wegovy pills had crossed three million prescriptions in the United States within slightly more than five months of launch. This indicates considerable consumer interest in oral alternatives to injectable weight-loss treatments.

b.  United Kingdom

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved oral Wegovy on 11 June 2026.

The medicine was authorised for adults with obesity or overweight accompanied by at least one weight-related medical condition.

However, regulatory approval did not automatically provide access through the National Health Service (NHS). At the time of approval, NHS access was subject to further assessment.

The international response demonstrates the commercial potential of oral obesity medicines.

5. Which Patients Can Use Wegovy Pills?

Wegovy is not intended as a general weight-loss supplement. It is a prescription medicine for patients meeting specific medical criteria.  Under the approved weight-management indications, eligible adults generally include:

v People with a Body Mass Index (BMI) of 30 or above, classified as having obesity.

v People with a BMI of 27 or above but below 30 who also have at least one weight-related medical condition.

Examples of associated conditions include:

§  High blood pressure.

§  Abnormal cholesterol levels.

§  Cardiovascular disease.

§  Obstructive sleep apnoea.

§  Other obesity-related health complications.

The medicine is intended to be used alongside a reduced-calorie diet and increased physical activity.  A doctor must evaluate the patient's medical history, existing medication, weight-management requirements, and potential risks before prescribing it.

People with certain medical conditions, including a history of specific thyroid cancers or serious gastrointestinal problems, may require particular caution or may not be suitable candidates.

6. Benefits of Wegovy Pills

The introduction of oral Wegovy offers several potential benefits.

a. No Weekly Injections

One of the most obvious advantages is convenience.

Patients who dislike needles or experience anxiety about injections may prefer a tablet.

b. Appetite Control

Semaglutide acts on appetite-regulating pathways in the brain. It helps patients feel satisfied with smaller quantities of food.

This may reduce unnecessary snacking and excessive calorie consumption.

c. Meaningful Weight Reduction

Clinical research has demonstrated substantial average weight reduction among participants receiving oral semaglutide.

However, individual results differ depending on treatment adherence, lifestyle, medical conditions, and other factors.

d. Potential Cardiovascular Benefits

Semaglutide-based Wegovy treatment also has an approved cardiovascular risk-reduction indication for certain eligible patients with established cardiovascular disease.

This is particularly relevant because obesity is associated with several cardiovascular complications.

e. Easier Integration into Daily Routines

A daily tablet may be more acceptable to patients who prefer oral medication.

Nevertheless, the tablet has strict administration requirements, which patients must follow carefully.

f. Effectiveness: What Does Clinical Research Say?

The effectiveness of oral Wegovy has been investigated through clinical trials.  One important study is the OASIS 4 trial, which evaluated once-daily oral semaglutide 25 mg in adults with overweight or obesity.

The study involved 307 participants who received either semaglutide or a placebo, alongside lifestyle interventions.

After 64 weeks, the results showed:

These findings demonstrate that oral semaglutide can produce meaningful weight reduction when combined with lifestyle changes.  However, the results represent clinical-trial averages and should not be interpreted as guaranteed outcomes for every patient.

The study was published in the New England Journal of Medicine in September 2025.

7.  Possible Side Effects and Safety Concerns

Although Wegovy offers potential benefits, it can also cause side effects.

The commonly reported problems include:

v Nausea.

v Vomiting.

v Diarrhoea.

v Constipation.

v Abdominal discomfort.

v Bloating.

v Reduced appetite.

These symptoms are often more noticeable when treatment begins or when the dose increases. More serious but less common concerns include pancreatitis, gallbladder complications, dehydration-related kidney problems, and certain vision-related complications.

Patients should seek medical attention if they experience severe or persistent abdominal pain, repeated vomiting, or other worrying symptoms.

Important precautions:

ü Do not use Wegovy without a doctor's prescription.

ü Follow the prescribed dose-escalation schedule.

ü Inform the doctor about existing medicines and medical conditions.

ü Tell healthcare professionals about Wegovy use before surgery or procedures involving anaesthesia.

ü Do not combine different semaglutide products without medical advice.

Wegovy is not a substitute for balanced nutrition, regular physical activity, or appropriate medical care.

8.  Conclusion

Australia's approval of oral Wegovy represents an important development in the treatment of obesity. By introducing a daily semaglutide tablet, Novo Nordisk has expanded the available treatment options for patients who prefer oral medicines over weekly injections.

Clinical evidence from the OASIS 4 trial demonstrates meaningful weight reduction, while the medicine's appetite-regulating mechanism offers additional support for long-term weight management.

Nevertheless, the medicine is not an instant weight-loss solution. Its effectiveness depends on appropriate medical supervision, dietary changes and regular physical activity.

Although the TGA has approved the tablets, their Australian commercial launch, retail pricing and wider accessibility remain important developments to watch.